ASX - By Stock
|
NUZ |
Re:
Ann: Appendix 4C & Quarterly Update
|
|
Densy
|
104 |
23K |
9 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
104
|
23K
|
9
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Densy
|
1.4K |
393K |
32 |
18/04/24 |
18/04/24 |
ASX - By Stock
|
1.4K
|
393K
|
32
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: PharmAust makes Head of Manufacturing appointment
|
|
Densy
|
37 |
10K |
20 |
18/04/24 |
18/04/24 |
ASX - By Stock
|
37
|
10K
|
20
|
|
ASX - By Stock
|
NUZ |
Re:
PharmAust media thread
|
|
Densy
|
317 |
87K |
19 |
17/04/24 |
17/04/24 |
ASX - By Stock
|
317
|
87K
|
19
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Densy
|
1.4K |
393K |
36 |
06/04/24 |
06/04/24 |
ASX - By Stock
|
1.4K
|
393K
|
36
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Densy
|
1.4K |
393K |
29 |
05/04/24 |
05/04/24 |
ASX - By Stock
|
1.4K
|
393K
|
29
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
The Great Pharmaust FDA ODD Approval Sweepstake
|
|
Densy
|
222 |
53K |
3 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
222
|
53K
|
3
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Media clarification
|
|
Densy
|
62 |
19K |
14 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
62
|
19K
|
14
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Media clarification
|
|
Densy
|
62 |
19K |
29 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
62
|
19K
|
29
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Media clarification
|
|
Densy
|
62 |
19K |
20 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
62
|
19K
|
20
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Media clarification
|
|
Densy
|
62 |
19K |
7 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
62
|
19K
|
7
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Media clarification
|
|
Densy
|
62 |
19K |
23 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
62
|
19K
|
23
|
|
ASX - By Stock
|
NUZ |
Re:
Top 200 PAA Shareholders as at 28 March 2024
|
|
Densy
|
55 |
16K |
1 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
55
|
16K
|
1
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Media clarification
|
|
Densy
|
62 |
19K |
32 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
62
|
19K
|
32
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Media clarification
|
|
Densy
|
62 |
19K |
17 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
62
|
19K
|
17
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Densy
|
1.4K |
393K |
41 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
1.4K
|
393K
|
41
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: PharmAust to present at NWR Virtual Healthcare Conference
|
|
Densy
|
126 |
35K |
14 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
126
|
35K
|
14
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: PharmAust to present at NWR Virtual Healthcare Conference
|
|
Densy
|
126 |
35K |
25 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
126
|
35K
|
25
|
|
ASX - By Stock
|
NUZ |
Re:
PharmAust media thread
|
|
Densy
|
317 |
87K |
35 |
17/03/24 |
17/03/24 |
ASX - By Stock
|
317
|
87K
|
35
|
|
ASX - By Stock
|
NUZ |
Re:
Big Pharma buyouts.
|
|
Densy
|
39 |
10K |
11 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
39
|
10K
|
11
|
|
ASX - By Stock
|
NUZ |
Re:
Big Pharma buyouts.
|
|
Densy
|
39 |
10K |
22 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
39
|
10K
|
22
|
|
ASX - By Stock
|
NUZ |
Re:
Amylyx class action Relyvrio
|
|
Densy
|
58 |
16K |
42 |
09/03/24 |
09/03/24 |
ASX - By Stock
|
58
|
16K
|
42
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Application for quotation of securities - PAA
|
|
Densy
|
77 |
22K |
16 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
77
|
22K
|
16
|
|
ASX - By Stock
|
NUZ |
Re:
PharmAust media thread
|
|
Densy
|
317 |
87K |
5 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
317
|
87K
|
5
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Densy
|
1.4K |
393K |
8 |
04/03/24 |
04/03/24 |
ASX - By Stock
|
1.4K
|
393K
|
8
|
|
ASX - By Stock
|
NUZ |
Re:
PharmAust media thread
|
|
Densy
|
317 |
87K |
20 |
04/03/24 |
04/03/24 |
ASX - By Stock
|
317
|
87K
|
20
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Densy
|
1.4K |
393K |
15 |
04/03/24 |
04/03/24 |
ASX - By Stock
|
1.4K
|
393K
|
15
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Densy
|
1.4K |
393K |
12 |
04/03/24 |
04/03/24 |
ASX - By Stock
|
1.4K
|
393K
|
12
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Extension Study Begins, Analysis Suggests Survival Benefit
|
|
Densy
|
197 |
57K |
20 |
21/02/24 |
21/02/24 |
ASX - By Stock
|
197
|
57K
|
20
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Densy
|
1.4K |
393K |
56 |
19/02/24 |
19/02/24 |
ASX - By Stock
|
1.4K
|
393K
|
56
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Canine Trial Update
|
|
Densy
|
126 |
30K |
8 |
17/07/23 |
17/07/23 |
ASX - By Stock
|
126
|
30K
|
8
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Canine Trial Update
|
|
Densy
|
126 |
30K |
26 |
16/07/23 |
16/07/23 |
ASX - By Stock
|
126
|
30K
|
26
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Results show MPL suppresses biomarkers associated with MND
|
|
Densy
|
200 |
45K |
24 |
11/07/23 |
11/07/23 |
ASX - By Stock
|
200
|
45K
|
24
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Results show MPL suppresses biomarkers associated with MND
|
|
Densy
|
200 |
45K |
14 |
11/07/23 |
11/07/23 |
ASX - By Stock
|
200
|
45K
|
14
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Commencement of Cohort 3 in Phase 1/2 MND Trial
|
|
Densy
|
151 |
33K |
9 |
16/06/23 |
16/06/23 |
ASX - By Stock
|
151
|
33K
|
9
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Commencement of Cohort 3 in Phase 1/2 MND Trial
|
|
Densy
|
151 |
33K |
12 |
15/06/23 |
15/06/23 |
ASX - By Stock
|
151
|
33K
|
12
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Commencement of Cohort 3 in Phase 1/2 MND Trial
|
|
Densy
|
151 |
33K |
6 |
13/06/23 |
13/06/23 |
ASX - By Stock
|
151
|
33K
|
6
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Commencement of Cohort 3 in Phase 1/2 MND Trial
|
|
Densy
|
151 |
33K |
2 |
13/06/23 |
13/06/23 |
ASX - By Stock
|
151
|
33K
|
2
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Commencement of Cohort 3 in Phase 1/2 MND Trial
|
|
Densy
|
151 |
33K |
8 |
13/06/23 |
13/06/23 |
ASX - By Stock
|
151
|
33K
|
8
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: PharmAust MND Trial Interim Analysis PK Outcomes
|
|
Densy
|
105 |
28K |
14 |
10/06/23 |
10/06/23 |
ASX - By Stock
|
105
|
28K
|
14
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: PharmAust MND Trial Interim Analysis PK Outcomes
|
|
Densy
|
105 |
28K |
7 |
08/06/23 |
08/06/23 |
ASX - By Stock
|
105
|
28K
|
7
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: PharmAust MND Trial Interim Analysis PK Outcomes
|
|
Densy
|
105 |
28K |
9 |
08/06/23 |
08/06/23 |
ASX - By Stock
|
105
|
28K
|
9
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: PharmAust MND Trial Interim Analysis PK Outcomes
|
|
Densy
|
105 |
28K |
27 |
08/06/23 |
08/06/23 |
ASX - By Stock
|
105
|
28K
|
27
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Canine Trial Update
|
|
Densy
|
205 |
45K |
6 |
07/06/23 |
07/06/23 |
ASX - By Stock
|
205
|
45K
|
6
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: PharmAust MND Trial Interim Analysis PK Outcomes
|
|
Densy
|
105 |
28K |
7 |
07/06/23 |
07/06/23 |
ASX - By Stock
|
105
|
28K
|
7
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Trading Halt
|
|
Densy
|
85 |
20K |
13 |
06/06/23 |
06/06/23 |
ASX - By Stock
|
85
|
20K
|
13
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Trading Halt
|
|
Densy
|
85 |
20K |
8 |
06/06/23 |
06/06/23 |
ASX - By Stock
|
85
|
20K
|
8
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Trading Halt
|
|
Densy
|
85 |
20K |
5 |
06/06/23 |
06/06/23 |
ASX - By Stock
|
85
|
20K
|
5
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Trading Halt
|
|
Densy
|
85 |
20K |
6 |
06/06/23 |
06/06/23 |
ASX - By Stock
|
85
|
20K
|
6
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Trading Halt
|
|
Densy
|
85 |
20K |
7 |
06/06/23 |
06/06/23 |
ASX - By Stock
|
85
|
20K
|
7
|
|